PAFAH1B1

Mutation & survival
SurvivalMutationKaplan–Meier · TCGA cohorts

Across TCGA pan-cancer cohorts, PAFAH1B1 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated PAFAH1B1 data layer compared with 24 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher PAFAH1B1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PAFAH1B1 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

ESCA and UCEC are the cancer types where PAFAH1B1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.
LineageMeasureSplitStageAUC1
high
AUC2
low
pSampling consensus
ESCAOSMedianIII,IV0.1020.574<.00112view →
UCECDFSMedianAll0.9280.618.0178view →
Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

PAFAH1B1–ESCA (OS)

Kaplan–Meier survival curve for PAFAH1B1 mutant vs wild-type samples in ESCA.

Open the ESCA breakdown →

Exploration